|
nasdaq:agtc
|
1072975
|
Apr 21st, 2024 12:00AM
|
AGTC
|
6.7K
|
118.00
|
Open
|
|
Apr 20th, 2024 10:47PM
|
Apr 20th, 2024 10:47PM
|
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years.
AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products
Find AGTC on YouTube at goo.gl/sMdJqX.
|
Open
|
|
Open
|
14193 NW 119th Terrace, Suite #10
|
Alachua
|
Florida
|
US
|
32615
|
|
Applied Genetic Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:agtc
|
1072975
|
Apr 20th, 2024 12:00AM
|
AGTC
|
6.7K
|
118.00
|
Open
|
|
Apr 19th, 2024 10:37PM
|
Apr 20th, 2024 04:30PM
|
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years.
AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products
Find AGTC on YouTube at goo.gl/sMdJqX.
|
Open
|
|
Open
|
14193 NW 119th Terrace, Suite #10
|
Alachua
|
Florida
|
US
|
32615
|
|
Applied Genetic Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:agtc
|
1072975
|
Apr 19th, 2024 12:00AM
|
AGTC
|
6.7K
|
118.00
|
Open
|
|
Apr 18th, 2024 10:46PM
|
Apr 18th, 2024 10:46PM
|
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years.
AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products
Find AGTC on YouTube at goo.gl/sMdJqX.
|
Open
|
|
Open
|
14193 NW 119th Terrace, Suite #10
|
Alachua
|
Florida
|
US
|
32615
|
|
Applied Genetic Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:agtc
|
1072975
|
Apr 18th, 2024 12:00AM
|
AGTC
|
6.7K
|
118.00
|
Open
|
|
Apr 17th, 2024 10:46PM
|
Apr 18th, 2024 05:50PM
|
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years.
AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products
Find AGTC on YouTube at goo.gl/sMdJqX.
|
Open
|
|
Open
|
14193 NW 119th Terrace, Suite #10
|
Alachua
|
Florida
|
US
|
32615
|
|
Applied Genetic Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:agtc
|
1072975
|
Apr 17th, 2024 12:00AM
|
AGTC
|
6.7K
|
118.00
|
Open
|
|
Apr 16th, 2024 10:35PM
|
Apr 17th, 2024 02:13PM
|
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years.
AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products
Find AGTC on YouTube at goo.gl/sMdJqX.
|
Open
|
|
Open
|
14193 NW 119th Terrace, Suite #10
|
Alachua
|
Florida
|
US
|
32615
|
|
Applied Genetic Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:agtc
|
1072975
|
Apr 16th, 2024 12:00AM
|
AGTC
|
6.7K
|
120.00
|
Open
|
|
Apr 15th, 2024 10:35PM
|
Apr 16th, 2024 10:30AM
|
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years.
AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products
Find AGTC on YouTube at goo.gl/sMdJqX.
|
Open
|
|
Open
|
14193 NW 119th Terrace, Suite #10
|
Alachua
|
Florida
|
US
|
32615
|
|
Applied Genetic Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:agtc
|
1072975
|
Apr 15th, 2024 12:00AM
|
AGTC
|
6.7K
|
120.00
|
Open
|
|
Apr 14th, 2024 10:37PM
|
Apr 15th, 2024 04:11PM
|
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years.
AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products
Find AGTC on YouTube at goo.gl/sMdJqX.
|
Open
|
|
Open
|
14193 NW 119th Terrace, Suite #10
|
Alachua
|
Florida
|
US
|
32615
|
|
Applied Genetic Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:agtc
|
1072975
|
Apr 14th, 2024 12:00AM
|
AGTC
|
6.7K
|
120.00
|
Open
|
|
Apr 13th, 2024 10:31PM
|
Apr 13th, 2024 10:31PM
|
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years.
AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products
Find AGTC on YouTube at goo.gl/sMdJqX.
|
Open
|
|
Open
|
14193 NW 119th Terrace, Suite #10
|
Alachua
|
Florida
|
US
|
32615
|
|
Applied Genetic Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:agtc
|
1072975
|
Apr 13th, 2024 12:00AM
|
AGTC
|
6.7K
|
120.00
|
Open
|
|
Apr 12th, 2024 10:21PM
|
Apr 13th, 2024 10:58AM
|
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years.
AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products
Find AGTC on YouTube at goo.gl/sMdJqX.
|
Open
|
|
Open
|
14193 NW 119th Terrace, Suite #10
|
Alachua
|
Florida
|
US
|
32615
|
|
Applied Genetic Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:agtc
|
1072975
|
Apr 12th, 2024 12:00AM
|
AGTC
|
6.7K
|
121.00
|
Open
|
|
Apr 11th, 2024 10:25PM
|
Apr 12th, 2024 07:53AM
|
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years.
AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products
Find AGTC on YouTube at goo.gl/sMdJqX.
|
Open
|
|
Open
|
14193 NW 119th Terrace, Suite #10
|
Alachua
|
Florida
|
US
|
32615
|
|
Applied Genetic Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|